R&D In Brief

 
• By Pharmaceutical Approvals Monthly

Cell Therapeutics completes enrollment in pixantrone Phase III trial; Elixir Pharmaceuticals type 2 drug mitiglinide enters final Phase III; Takeda stops development of cholesterol compound TAK-475 (lapaquistat); more R&D news, in brief

More from Archive

More from Pink Sheet